Ipca Laboratories Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1544 as of 04 May 11:08 . The P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 years The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Ipca Laboratories Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Sanjivani Paranteral Ltd?

Market cap of Ipca Laboratories Ltd is 38,847 Cr while Market cap of Sanjivani Paranteral Ltd is 196 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Sanjivani Paranteral Ltd?

The stock performance of Ipca Laboratories Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Sanjivani Paranteral Ltd?

As of May 4, 2026, the Ipca Laboratories Ltd stock price is INR ₹1531.2. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹160.0.

How do dividend payouts of Ipca Laboratories Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.